Luspatercept for low blood counts with gene change (CCUS)
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a drug called luspatercept for people with a condition called CCUS, where they have low blood counts and a gene change. The goal is to see if the drug can improve blood counts and reduce symptoms like fatigue or bleeding risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a diagnosis of CCUS (low blood counts with a specific gene change).
- You must have significant low blood counts that need treatment (like anemia requiring transfusions, or low platelets with bleeding risk).
- You must be able to perform daily activities (ECOG score 0-2).
- Your liver and kidney function must be adequate.
- You must agree to use birth control if you could become pregnant or get someone pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called luspatercept to see if it can raise hemoglobin levels in people with anemia caused by chronic kidney disease. It's for those whose current treatments aren't working well or who cannot use them.
This Phase 2 trial studies whether luspatercept can improve anemia in people with lower-risk myelodysplastic syndrome (MDS) who do not currently need red-blood-cell transfusions. It’s also looking to see if the benefit is similar whether or not you have ring sideroblasts.
This Phase 2 trial studies luspatercept to improve anemia (low red blood cells) in people with MDS that has a del5q change. It also checks safety, especially for people who need red blood cell transfusions and have not benefited from prior standard treatments.
This study tests a medicine called luspatercept to see if it can help people with alpha thalassemia need fewer blood transfusions. It is for adults and some teens with this condition.
This trial is testing whether a combination of two drugs, luspatercept and darbepoetin alfa, can help people with lower-risk myelodysplastic syndromes (MDS) who need frequent red blood cell transfusions. The goal is to see if the combination reduces their need for transfusions.
This trial tests whether luspatercept can help improve low red blood cell counts (anemia) that happens soon after a stem cell transplant. It is for people with blood cancers who have very low hemoglobin after transplant.
Hear when a new Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.